Avecho Biotechnology Limited (AVEFF)
Avecho Biotechnology Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Clayton, VIC, AU. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $17.4M. On trailing twelve-month figures it carries a trailing P/E of -14.29, a net margin of -248.7%. Its beta of 1.11 implies it has historically moved more than the broad market.
Avecho Biotechnology Limited is an Australian-based firm specializing in the development, production, and sale of various products. Central to its operations is the proprietary and patented Targeted Penetration Matrix (TPM) drug delivery system, which the company leverages across the pharmaceutical, skincare, animal health, and nutrition industries. Its product portfolio includes TPM and Vital ET, which are incorporated into drug delivery systems and cosmetic formulations. The company is also actively engaged in the development of TPM/Oxymorphone and TPM/Oxycodone. For human health, Avecho's offerings facilitate drug administration through diverse methods such as gels, injectables, and transdermal patches. Additionally, it provides non-antibiotic feed additives aimed at enhancing the health and feed efficiency of livestock. Avecho demonstrates its commitment to research through a collaboration with the Lambert Initiative at the University of Sydney, jointly conducting a study to explore the potential of topically applied cannabidiol for alleviating osteoarthritis symptoms. The company's reach extends internationally, serving clients in Australia, Switzerland, India, and other global markets. Founded in 1992, the company was previously known as Phosphagenics Limited before adopting the name Avecho Biotechnology Limited in May 2019. Its headquarters are situated in Clayton, Australia.
Avecho Biotechnology Limited is most often compared with the following Healthcare names: